Pacira reports Q3 EPS 70c, consensus 65c

Reports Q3 revenue $179.52M, consensus $182.33M. “Pacira (PCRX) delivered another quarter of strong execution across our corporate, clinical, and commercial initiatives, underscoring the momentum behind our 5×30 growth strategy,” said Frank D. Lee, chief executive officer of Pacira BioSciences. “With accelerating topline growth, expanding market access, and meaningful pipeline advancements, including the in-licensing of AMT-143, we believe we are well positioned to expand our leadership in musculoskeletal pain and adjacencies. I’m proud of our team’s continued focus and discipline, which are driving innovation, improving patient outcomes, and creating long-term value for our shareholders.”